The Mechanism of Catalpol to Improve Oxidative Damage of Dermal Fibroblasts Based on Nrf2/HO-1 Signaling Pathway
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s467569 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Xiaona Lang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Tianjin Hospital, Tianjin, People's Republic of China. Hauptthemen laut MEDLINE: Iridoid Glucosides, NF-E2-Related Factor 2, Fibroblasts, Oxidative Stress. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Tianjin Hospital, Tianjin, People's Republic of China.
- Orthopedic Department, Tianjin Hospital, Tianjin, People's Republic of China.
ORCID-Profile: Xiaona Lang
Zitieren
APA
Lang, X., Xu, L., Li, L., & Feng, X. (2024). The Mechanism of Catalpol to Improve Oxidative Damage of Dermal Fibroblasts Based on Nrf2/HO-1 Signaling Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s467569
Vancouver
Lang X, Xu L, Li L, Feng X. The Mechanism of Catalpol to Improve Oxidative Damage of Dermal Fibroblasts Based on Nrf2/HO-1 Signaling Pathway. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s467569
BibTeX
@article{Lang2024,
author = {Lang, Xiaona and Xu, Liyan and Li, Lu and Feng, Xin},
title = {The Mechanism of Catalpol to Improve Oxidative Damage of Dermal Fibroblasts Based on Nrf2/HO-1 Signaling Pathway},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s467569}
}
EUVIMED